CINECA IRIS Institutional Research Information System

FERRANNINI, ELEUTERIO Statistiche

FERRANNINI, ELEUTERIO  

DIP. DI MEDICINA CLINICA E SPERIMENTALE - disattivato (attivo dal 19/09/2012 al 31/12/2019)  

Mostra records
Risultati 1 - 20 di 659 (tempo di esecuzione: 0.037 secondi).
Titolo Data di pubblicazione Autore(i) File
HPLC-MS/MS method for simultaneous analysis of plasma 2-hydroxybutyrate and 2-hydroxyisobutyrate: Development and clinical significance 1-gen-2025 Campi, Beatrice; Vitelli, Valentina; Saponaro, Federica; Zucchi, Riccardo; Ferrannini, Ele; Saba, Alessandro
Association between glycosuria and albuminuria in patients with type 2 diabetes from the CREDENCE trial: a mechanistic link? 1-gen-2024 Ferrannini, E.; Solini, A.; Natali, A.
Effects of hypertriglyceridemia with or without NEFA elevation on β-cell function and insulin clearance and sensitivity 1-gen-2024 Tricò, Domenico; Rebelos, Eleni; Astiarraga, Brenno; Baldi, Simona; Scozzaro, Tiziana; Sacchetta, Luca; Chiriacò, Martina; Mari, Andrea; Ferrannini, Ele; Muscelli, Elza; Natali, Andrea
GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss 1-gen-2024 Della Pepa, Giuseppe; Patrício, Bárbara G.; Carli, Fabrizia; Sabatini, Silvia; Astiarraga, Brenno; Ferrannini, Ele; Camastra, Stefania; Gastaldelli, Amalia
Renal Cortical Glucose Uptake Is Decreased in Insulin Resistance and Correlates Inversely With Serum Free-fatty Acids 1-gen-2024 Rebelos, Eleni; Mari, Andrea; Honka, Miikka-Juhani; Pekkarinen, Laura; Latva-Rasku, Aino; Laurila, Sanna; Rajander, Johan; Salminen, Paulina; Iida, Hidehiro; Ferrannini, Ele; Nuutila, Pirjo
Role of Glycosuria in SGLT2 Inhibitor–Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial 1-gen-2024 Ferrannini, Ele; Solini, Anna; Baldi, Simona; Scozzaro, Tiziana; Polidori, David; Natali, Andrea; Hansen, Michael K.
SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study 1-gen-2024 Latva-Rasku, A.; Rempelou, E.; Tuisku, J.; Aarnio, R.; Bhowmik, A.; Keskinen, H.; Laurila, S.; Lahesmaa-Hatting, M.; Pekkarinen, L.; Isackson, H.; Kirjavainen, A. K.; Koffert, J.; Heurling, K.; Nummenmaa, L.; Ferrannini, E.; Oldgren, J.; Oscarsson, J.; Nuutila, P.
Empagliflozin and renal sodium-hydrogen exchange in healthy subjects 1-gen-2023 Biancalana, Edoardo; Rossi, Chiara; Raggi, Francesco; Distaso, Mariarosaria; Tricò, Domenico; Baldi, Simona; Ferrannini, Ele; Solini, Anna
Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE 1-gen-2023 Ferrannini, Giulia; Pollock, Carol; Natali, Andrea; Yavin, Yshai; Mahaffey, Kenneth W; Ferrannini, Ele
Renal Perfusion, Oxygenation and Metabolism: The Role of Imaging 1-gen-2023 Päivärinta, Johanna; Anastasiou, Ioanna A; Koivuviita, Niina; Sharma, Kanishka; Nuutila, Pirjo; Ferrannini, Ele; Solini, Anna; Rebelos, Eleni
Differential effects of bariatric surgery on plasma levels of ANGPTL3 and ANGPTL4 1-gen-2022 Bini, Simone; D'Erasmo, Laura; Astiarraga, Brenno; Minicocci, Ilenia; Palumbo, Maria; Pecce, Valeria; Polito, Luca; Di Costanzo, Alessia; Haeusler, Rebecca A; Arca, Marcello; Ferrannini, Ele; Camastra, Stefania
Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans 1-gen-2022 Ferrannini, Eleuterio; Manca, MARIA LAURA; Ferrannini, Giulia; Andreotti, Felicita; Andreini, Daniele; Latini, Roberto; Magnoni, Marco; Williams, Stephen A.; Maseri, Attilio; Maggioni, Aldo P.
Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes 1-gen-2022 Tricò, Domenico; Raggi, Francesco; Distaso, Mariarosaria; Ferrannini, Ele; Solini, Anna
Hepatic FoxOs link insulin signaling with plasma lipoprotein metabolism through an apolipoprotein M/sphingosine-1-phosphate pathway 1-gen-2022 Izquierdo, M. C.; Shanmugarajah, N.; Lee, S. X.; Kraakman, M. J.; Westerterp, M.; Kitamoto, T.; Harris, M.; Cook, J. R.; Gusarova, G. A.; Zhong, K.; Marbuary, E.; O-Sullivan, I.; Rasmus, N.; Camastra, S.; Unterman, T. G.; Ferrannini, E.; Hurwitz, B. E.; Haeusler, R. A.
Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review 1-gen-2022 Camastra, S.; Ferrannini, E.
Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review 1-gen-2022 Camastra, Stefania; Ferrannini, Ele
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes 1-gen-2021 Grespan, E.; Giorgino, T.; Natali, A.; Ferrannini, E.; Mari, A.
Differential metabolomic signatures of declining renal function in Types 1 and 2 diabetes 1-gen-2021 Manca, Maria Laura; Solini, Anna; Haukka, Jani K; Sandholm, Niina; Forsblom, Carol; Groop, Per-Henrik; Ferrannini, Ele
Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study 1-gen-2021 Oldgren, J.; Laurila, S.; Akerblom, A.; Latva-Rasku, A.; Rempelou, E.; Isackson, H.; Saarenhovi, M.; Eriksson, O.; Heurling, K.; Johansson, E.; Wilderang, U.; Karlsson, C.; Esterline, R.; Ferrannini, E.; Oscarsson, J.; Nuutila, P.
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence 1-gen-2021 Natali, A.; Nesti, L.; Trico, D.; Ferrannini, E.